biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s): BIOAF

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs

Bullboard Posts

Comment by buddy2021on Dec 04, 2017 12:27pm

126 Views

Post# 27085737

RE:RE:RE:RE:RE:Bioasis Implements Transition Plan for Board of Directors

Excellent summary. I was at the Calgary mtg and couldn't have said it better. Every one previous did what they could to get BTI the opportunities it has today. It was recognised and a thank you was given particularly to Rob. Key personnel have been retained on the science side of the business.

Pull the bandaid off quickly, identify what you have on the science end, build a rock star team and move forward in a methodical and expedient manner. Now some regular "real" updates. A plan well executed. Good job MD.

Bullboard Posts

Consumer advocacy law firm investigates Microsoft over X-Box data concerns